Starting January 1, Eli Lilly & Co. and Novo Nordisk will sell their weight-loss drugs Zepbound and Wegovy directly to employers through a program with Waltz Health, bypassing traditional pharmacy benefit managers. The initiative will offer the drugs at fixed up-front prices, aiming to make them more accessible and affordable for employees.
Full Story: BenefitsPRO (free registration) (11/21)